Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Tolerability and Immunogenicity of SCB-1019T in Adults Who Were Vaccinated With AREXVY at Least 18 Months Before

NCT06843317 is registered in ClinicalTrials.gov with Clover Biopharmaceuticals USA, LLC as lead sponsor.

NCT NCT06843317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06843317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Tolerability and Immunogenicity of SCB-1019T in Adults Who Were Vaccinated With AREXVY at Least 18 Months Before
Lead sponsor
Clover Biopharmaceuticals USA, LLC
Phase
Phase 1
Overall status
Recruiting
Start date
March 21, 2025
Completion date
June 3, 2026
Enrollment
160 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

rsv infection